Announcements Trials

Browse Landscape

Phase

Phase 2 2 Phase 1 2 Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Follicular 6 Prostatic Neoplasms 2 Lymphoma, Large B-Cell, Diffuse 2 Urinary Bladder Neoplasms 1 Sarcoma, Synovial 1 Sarcoma 1 Rhabdoid Tumor 1 Multiple Myeloma 1 Mesothelioma 1 Melanoma 1 Lymphoma, T-Cell, Peripheral 1 Lymphoma, Non-Hodgkin 1 Lymphoma, B-Cell 1 Lymphoma 1 Hematologic Neoplasms 1 Chordoma 1 Carcinoma, Transitional Cell 1

Interventions

Rituximab 47 Cyclophosphamide 45 fludarabine 22 Filgrastim 21 Lenalidomide 18 fludarabine phosphate 17 Prednisone 16 Radiotherapy 15 Peripheral Blood Stem Cell Transplantation 15 Etoposide 15 Vincristine 14 Doxorubicin 14 Melphalan 13 Busulfan 13 pembrolizumab 11 Tacrolimus 11 Methotrexate 10 Gemcitabine 10 ibrutinib 9 Bendamustine Hydrochloride 9 Alemtuzumab 9 obinutuzumab 8 Bortezomib 8 Vorinostat 7 Mycophenolic Acid 7 Granulocyte Colony-Stimulating Factor 7 Carboplatin 7 Azacitidine 7 venetoclax 6 Whole-Body Irradiation 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Lymphoma × tazemetostat × Clear all

NCT02889523 2024-10-09

Epi-RCHOP

The Lymphoma Academic Research Organisation

Phase 1/2 Active not recruiting

Lymphoma, Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon ⚡